CAR-T immunotherapy has revolutionized blood cancer treatment. It fails against solid tumors. The reason is concentration: solid tumors express target antigens at levels too low for conventional CAR-T cells to detect. The engineered immune cells patrol the body looking for cancer markers, but when those markers are sparse — scattered across the tumor surface at a tenth or a fiftieth of the expected density — the CAR-T cells pass by without engaging.
Published in Science, researchers engineered a new type of receptor called a HIT receptor — HLA-Independent T cell receptor — that detects cancer antigens at concentrations 10 to 50 times lower than existing CAR-T therapies. They demonstrated that CD70, a surface protein, is expressed on 100% of cancer cells in some solid tumors, including cells previously classified as “CD70-negative.” The cells were not negative — the detection was insensitive. HIT CAR-T cells eliminated kidney, ovarian, and pancreatic tumors in mice. CD70 is expressed across more than 20 solid tumor types.
The structural insight is about the relationship between detection threshold and target availability. The problem was framed as “solid tumors lack good targets.” The HIT receptor revealed that the targets were always there, at concentrations below the detection threshold of existing therapies. Lowering the threshold did not change the biology of the tumor — it changed what the immune system could see. The cells classified as antigen-negative were antigen-present at a level the instrument could not measure. The boundary between targetable and untargetable cancer was not a fact about cancer. It was a fact about the sensitivity of the weapon aimed at it.